Ocugen (OCGN)
(Delayed Data from NSDQ)
$0.99 USD
-0.04 (-3.53%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $0.99 0.00 (-0.36%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
OCGN 0.99 -0.04(-3.53%)
Will OCGN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for OCGN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for OCGN
Ocugen (OCGN) Reports Q2 Loss, Misses Revenue Estimates
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
OCGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Cooper Companies Q1 Earnings Likely to Reflect Seasonal Trends
5 Biotech Breakthrough Stocks to Watch in 2025
Ocugen (OCGN) Reports Q3 Loss, Misses Revenue Estimates
Other News for OCGN
Ocugen Inc (OCGN) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
Ocugen (OCGN) Advances Gene Therapy Initiatives Amidst Strategic Changes
Q2 2025 Ocugen Inc Earnings Call Transcript
Ocugen, Inc. (OCGN) Q2 2025 Earnings Call Transcript
Ocugen outlines three licensing applications and 2026 commercialization plans while advancing gene therapy trials